Liminatus Pharma, Inc. Class A Common Stock (LIMN) Research

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Market snapshot

Symbol
LIMN
Price
$0.12
Day change
-2.30%
Market cap
$3.2M
P/E ratio
-0.26x
52-week range
0.111-33.66
Sector
Healthcare
Industry
Biotechnology

Recent news

  • Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session

    Liminatus Pharma Inc. shares soared in after-hours trading after the company announced a merger agreement with InnocsAI LLC.

Peer companies

  • Alterity Therapeutics Limited (ATHE)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Dyadic International, Inc. (DYAI)
  • Evaxion Biotech A/S (EVAX)
  • Generation Bio Co. (GBIO)
  • Jasper Therapeutics, Inc. (JSPR)
  • MAIA Biotechnology, Inc. (MAIA)
  • Mural Oncology plc (MURA)

Recent insider activity

  • Iris Acquisition Holdings LLC — trade (0 shares) on 2025-04-30
  • Lemons II Philip Wayne — trade (0 shares) on 2025-07-10
  • Baek Richard JaiHwan — trade (0 shares) on 2025-07-10
  • KH Feelux Co., Ltd — trade (0 shares) on 2025-04-30
  • Valetudo Therapeutics LLC — trade (0 shares) on 2025-04-30

Open Liminatus Pharma, Inc. Class A Common Stock (LIMN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.